According to a post on the FDA’s website, Kyverna Therapeutics’ treatment of stiff person syndrome received orphan designation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
- Kyverna Therapeutics reports Q2 EPS (67c), consensus (70c)
- Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Kyverna Therapeutics receives U.S. FDA RMAT designation for KYV-101
- JMP Securities healthcare analysts hold an analyst/industry conference call